SNDX — Syndax Pharmaceuticals, Inc.

Summary of Syndax Pharmaceuticals Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $172.4 million for 2025, with $124.8 million from Revuforj and $42.4 million from Niktimvo collaboration revenue.
• Revuforj Performance: Generated $125 million in net revenue in 2025, with a 38% increase in Q4 compared to Q3.
• Niktimvo Performance: Achieved $151.6 million in net revenue for 2025, with a 22% increase in Q4 compared to Q3.
• Collaboration Revenue: Syndax recorded $42.4 million from Niktimvo after deducting costs.
• Cash Position: Ended 2025 with $394 million in cash and equivalents, positioning the company well for future investments.

2. Strategic Updates and Business Highlights

• Product Launches: Successfully launched Revuforj and Niktimvo, with Revuforj's expanded label for NPM1 mutated AML driving significant growth.
• Market Penetration: Revuforj achieved approximately 50% penetration in the KMT2A incident population within the first year.
• Clinical Development: Advanced pipeline with pivotal trials for revumenib and axatilimab, including enrollment in a Phase II trial for idiopathic pulmonary fibrosis (IPF).
• Market Opportunities: Revuforj and Niktimvo represent a combined market opportunity exceeding $5 billion.

3. Forward Guidance and Outlook

• Revenue Growth: Anticipate continued growth in Revuforj and Niktimvo driven by expanding patient populations and increasing average duration of therapy.
• Expense Management: Projecting stable R&D and SG&A expenses of approximately $400 million for 2026, excluding non-cash stock compensation.
• Profitability: Expect to reach profitability without the need for additional capital, supported by growing revenues and stable expenses.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: While Syndax is optimistic about its product profiles, there is acknowledgment of competition in the market, particularly for NPM1 patients.
• Market Dynamics: The company must navigate the complexities of patient transitions from treatment to maintenance, especially in the KMT2A population.
• Regulatory Risks: Future trials and their outcomes will significantly impact the company’s strategic direction and market positioning.

5. Notable Q&A Insights

• Post-Transplant Maintenance Use: Increased from 35%-40% to 40%-45% in KMT2A patients, with expectations of reaching 70%-80% in the future.
• NPM1 Patient Starts: Currently at 30% of new patient starts; anticipated to grow as awareness and physician comfort with Revuforj increase.
• IPF Trial Expectations: Positive Phase II results could lead to a rapid transition to a pivotal Phase III trial, with plans for a subcutaneous regimen to enhance patient compliance.
• Combination Therapy: Approximately 40% of patients are being treated in combination with other therapies, indicating a growing trend that could enhance treatment duration and efficacy.

This summary encapsulates the key points from Syndax Pharmaceuticals' Q4 2025 earnings call, highlighting their financial performance, strategic initiatives, future outlook, and potential challenges.